People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Benefits associated with weight loss and lower insulin requirements In the clinical trial, semaglutide use led to lower insulin requirements and increased weight loss. It showed greater benefits ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Courtesy Staci Rice, Classified as a GLP-1, appetite-suppressing medications, semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes drug Ozempic.

Ozempic (semaglutide) helps people with type 2 diabetes lower their blood sugar if diet, exercise, and other diabetes medications haven’t worked. If you’ve just gotten a prescription for it ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group ...

EMINENT contributes to numerous pioneering studies investigating the role of Semaglutide and Tirzepatide in clinical trials. FREDERICK, MD, UNITED STATES, January 7, 2025 /EINPresswire.com ...